Real-world Comparative Study of Androgen Receptor Signaling Inhibitors in Japanese Patients With Non-metastatic Castration-resistant Prostate Cancer - PubMed
7 hours ago
- #ARSIs
- #nmCRPC
- #Japanese Study
- The study compared three androgen receptor signaling inhibitors (ARSIs) for non-metastatic castration-resistant prostate cancer (nmCRPC) in Japanese patients.
- Enzalutamide (ENZ) showed significantly longer progression-free survival (PFS) than apalutamide (APA), while darolutamide (DARO) had comparable outcomes.
- Overall survival did not differ significantly among the groups.
- First-line ARSI therapy resulted in longer PFS compared to second-line use.
- Starting ARSI treatment at PSA levels below 2.0 ng/ml improved PFS.
- Second-line ARSI therapy showed limited PSA response and shorter PFS.
- Adverse event-related dose reduction or discontinuation led to poorer PFS, with dermatologic toxicity being a main cause for APA discontinuation.